Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Rhea-AI Summary

Annovis (NYSE: ANVS) will present at the 2025 Annual Meeting of the Parkinson Study Group in San Diego, Dec 4-6, 2025.

The company will present Phase 3 Parkinson's disease biomarker data showing that patients with amyloid co-pathology experienced greater cognitive decline that was counteracted and reversed by buntanetap; buntanetap also reduced tau biomarkers. The poster includes a cross-study comparison of completed trials and highlights that patients with amyloid pathology show the largest cognitive gains.

Presentation: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients by Maria Maccecchini, Ph.D., on Dec 5 at 6:15 p.m. PST; data will be posted on the company website after the meeting.

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.

The presentation builds on momentum from the Company’s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity.

The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most – patients with amyloid pathology. In both Parkinson’s and Alzheimer’s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps.

Presentation details:

• Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients
• Presenter: Maria Maccecchini, Ph.D., President and CEO
• Format: Poster guided tour
• Time of presentation: December 5, 6:15 p.m. PST
  
  

The data presented at the meeting will be posted on the Company's website following the conference.

The PSG Annual Meeting brings together leading investigators, coordinators, trainees, advocates, and allied stakeholders to advance collaborative research and showcase the latest advances and best practices in PD.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com‍

FAQ

When will Annovis (ANVS) present at the Parkinson Study Group Annual Meeting?

Annovis will present at the PSG Annual Meeting in San Diego, Dec 4-6, 2025; the poster guided tour is on Dec 5 at 6:15 p.m. PST.

What Phase 3 PD data will Annovis (ANVS) present on Dec 5, 2025?

Phase 3 biomarker data showing buntanetap reversed cognitive decline in patients with amyloid co-pathology and reduced tau biomarkers.

Who is presenting Annovis's (ANVS) poster on buntanetap at PSG 2025?

Maria Maccecchini, Ph.D., President and CEO, is the presenter for the poster guided tour.

What is the title of Annovis's (ANVS) PSG 2025 presentation and its focus?

Title: 'Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients'; it focuses on amyloid co-pathology, cognitive outcomes, and biomarker changes.

Will Annovis (ANVS) publish the PSG 2025 presentation data online?

Yes, the company said the data presented at the meeting will be posted on the company website after the conference.

How do Annovis's (ANVS) cross-study results affect patient selection for buntanetap?

The cross-study comparison highlights that patients with biomarker-confirmed amyloid pathology showed the greatest cognitive gains following buntanetap.